| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.15 | 0.0009 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.18 | 0.0009 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.12 | 0.009 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.095 | 0.05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.083 | 0.1 |